Kamada (KMDA) Részvény Árfolyam
Kamada Árfolyam
Az árbevétel évi 14,8%-kal nőtt az elmúlt 19 évben 180,46 M USD-ra. Az egy részvényre jutó eredmény évi 31,8%-kal nőtt az elmúlt 13 évben. A(z) Kamada nettó árrés jelenleg 11,2%, emelkedett a néhány évvel ezelőtti -2,2%-hoz képest. A(z) Kamada osztalékhozama jelenleg körülbelül 2,60%. A kifizetési ráta a nyereség körülbelül 61%-a. Az elemzői célár mediánja 13,00 USD, ami felett a jelenlegi árat 68,8%-kal. 9 elemzőből 8 vételt javasol — az összesített konszenzus Vétel.
Kamada részvényár
Ezeket az adatokat az Eulerpool API-n keresztül
100 000 kérés/hó ingyen · nincs bankkártya
Kamada üzleti modell és részvényelemzés
Gyakran feltett kérdések a Kamada részvényről
The business model of Kamada Ltd revolves around the development, production, and commercialization of specialty plasma-derived protein therapeutics. Kamada focuses on three main areas: respiratory diseases, AAT Deficiency, and graft-versus-host disease. By utilizing advanced technologies and expertise in protein purification, Kamada aims to provide innovative solutions for patients and healthcare professionals. With its comprehensive portfolio of FDA-approved products and strategic partnerships, Kamada strives to improve the quality of life for individuals facing these medical conditions. As a leading biopharmaceutical company, Kamada Ltd leverages its extensive knowledge and resources to bring transformative therapies to the market.
Kamada Ltd is primarily active in the biopharmaceutical industry.
The main competitors of Kamada Ltd in the market are companies like Takeda Pharmaceutical Company Limited, CSL Limited, and Grifols, S.A. These companies also operate in the biopharmaceutical industry and offer similar products and services. However, Kamada Ltd distinguishes itself through its innovative research and development efforts, strong global presence, and a diverse product portfolio. Its commitment to technological advancements and strategic partnerships enables Kamada Ltd to stay competitive and maintain a significant market position.
Kamada Ltd is a pharmaceutical company based in Israel. Founded in 1990, the company specializes in the development and production of plasma-derived protein therapeutics. With a focus on rare diseases and respiratory conditions, Kamada's innovative therapies have gained recognition globally. The company has a strong track record of successful partnerships with leading pharmaceutical companies and has expanded its market reach across Europe, the United States, and other regions. Kamada's dedication to research and development has resulted in numerous approvals from regulatory authorities, enhancing its reputation as a leader in the biopharmaceutical industry. Through its commitment to providing life-saving treatments, Kamada Ltd continues to improve the well-being of patients worldwide.
Kamada Ltd has achieved several significant milestones throughout its operation. The company demonstrated its dedication to innovation and development by receiving approval for several therapeutic products. For instance, in 2011, Kamada obtained FDA approval for Glassia, its flagship treatment for Alpha-1 Antitrypsin Deficiency. Additionally, the company successfully launched AATscan, a diagnostic tool used for detecting the presence of Alpha-1 Antitrypsin Deficiency. Furthermore, Kamada established partnerships with renowned global pharmaceutical companies, expanding its market presence and enhancing its research and development capabilities. These accomplishments highlight Kamada Ltd's commitment to advancing medical solutions and solidify their position as a leading player in the healthcare industry.
Kamada Ltd is primarily present in multiple countries and regions worldwide. With a strong global presence, the company operates in various key markets, including the United States, Canada, Europe, Israel, and Latin America. Kamada Ltd's diversified geographical footprint enables it to reach a wide range of customers and expand its distribution network effectively.
Kamada Ltd represents values of innovation, dedication, and excellence. Committed to improving patients' lives, Kamada focuses on developing and commercializing plasma-derived protein therapeutics. With a corporate philosophy centered on integrity, transparency, and ethical conduct, the company aims to deliver high-quality treatments and meet the medical needs of diverse patient populations. By prioritizing research and development initiatives, Kamada strives to leverage its scientific expertise and technological advancements to address unmet medical needs. Through collaboration and partnership, Kamada Ltd is dedicated to making a positive impact in the healthcare industry, promoting patient well-being, and advancing medical advancements.
Az elemzők jelenleg 13,00 USD átlagos célárat adnak a Kamada részvényre (medián: 13,00 USD), ami +68,8 % a legutóbbi árhoz képest. A konszenzus 9 elemzői minősítésen alapul.
9 elemző értékeli jelenleg a Kamada részvényt: 8 vételt, 1 tartást és 0 eladást javasol. 2026-re az elemzők 202,96 M USD árbevételt és 0,45 USD EPS-t várnak a Kamada esetében.
Az aktuális árfolyamon a Kamada részvény 6,90 EUR (7,70 USD).
A Kamada részvény (KMDA) 2 tőzsdén jegyzett, többek között: NASDAQ (KMDA).
Kamada Ltd. is a biopharmaceutical company based in Israel that specializes in the development, manufacturing, and marketing of products for the treatment of various diseases. The company's business model is based on its ability to produce innovative products based on proteins that are relevant for the therapy of diseases such as Alpha-1 antit. The company's main areas of focus include the production of intravenous immunoglobulins (IVIG) for the treatment of severe immunodeficiency disorders. IVIG is also used in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus. Kamada is currently the only manufacturer of IVIG in Israel. The company's products are also available in Europe and the USA. Another important area of the company is the production of alpha-1 proteinase inhibitors (AAT) for the treatment of alpha-1 antitrypsin deficiency. This is an inherited disease that can lead to severe lung damage. Kamada has introduced the first AAT product manufactured in Israel to the market. It is also distributed in Europe and the USA. In addition to IVIG and AAT, Kamada also produces Factor VIII concentrates for the treatment of hemophilia and for blood clotting in patients who have received blood transfusions. The company also manufactures enzymes for the diagnosis of diseases and for research. Another business area of the company is the development of biosimilars, which mimic biological medicines that are already on the market. Kamada's biosimilars will help improve access to important therapies and relieve healthcare systems. Currently, the company is developing biosimilars for use in lung diseases and malignant diseases. Kamada's business model also includes collaboration with other companies in the biotechnology industry. The company has partnerships with leading companies such as Baxter, Shire, and Novartis to distribute or co-develop its products. In summary, Kamada's business model is focused on producing and marketing innovative products for the treatment of various diseases. The company specializes in protein production and has partnerships with other biotechnology companies. The different divisions of the company include the production of IVIG, AAT, Factor VIII concentrates, enzymes, and biosimilars. Kamada is also involved in the development of new products to meet patient needs and improve access to important therapies.
A várható bevétele Kamada 202,96 M USD. Ez az érték az aktuális pénzügyi adatokon alapul, és a vállalat üzleti teljesítményét tükrözi.
A várható nyeresége Kamada 27,54 M USD. A nettó nyereség a vállalat nyereségességét tükrözi az összes költség levonása után.
A Kamada ár/nyereség mutatója (P/E) jelenleg 17,24. A P/E mutató az aktuális részvényárat az egy részvényre jutó nyereséggel hasonlítja össze, és segít a befektetőknek a Kamada részvény értékelésének megértésében.
A Kamada ár/értékesítés mutatója (P/S) jelenleg 2,34. A P/S mutató a piaci kapitalizációt az éves bevételhez hasonlítja, és a Kamada részvény értékelési mérőszámaként szolgál.
Az Eulerpool minőségi pontszáma a Kamada számára 6/10.
A Kamada ISIN-je IL0010941198. Az ISIN (International Securities Identification Number) a nemzetközi securities azonosító.
A Kamada WKN-je A0JMEX. A WKN (Wertpapierkennnummer) egy hatjegyű német értékpapír-azonosító szám.
A Kamada ticker-e KMDA. A ticker szimbólum a Kamada részvény tőzsdei kereskedésénél használatos.
Kamada részvény
Kamada Peer Group
Kamada Tőzsdei rövidítés
Kamada FIGI
A Kamada összes alapfundamentuma és mélyreható elemzése
A Kamada részvény Eulerpool-elemzése olyan fontos pénzügyi mutatókat tartalmaz, mint a bevétel, nyereség, P/E arány, P/S arány, EBIT, valamint információk az osztalékról. Vizsgáljuk a részvények, piaci kapitalizáció, adósság, saját tőke és kötelezettségek vonatkozásait is Kamada. Ha részletesebb információt keres ezekről a témákról, részletes elemzéseket kínálunk az aloldalainkon.